

Raushan T Kurmasheva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8718534/publications.pdf>

Version: 2024-02-01

91
papers

2,568
citations

172457

29
h-index

214800

47
g-index

94
all docs

94
docs citations

94
times ranked

4522
citing authors

#	ARTICLE	IF	CITATIONS
1	Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 80-89.	2.1	2
2	PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma. <i>IScience</i> , 2022, 25, 103725.	4.1	3
3	Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 903-913.	4.1	12
4	Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models. <i>Clinical Cancer Research</i> , 2022, 28, 3836-3849.	7.0	2
5	In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28772.	1.5	9
6	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. <i>Cancer Research</i> , 2021, 81, 1076-1086.	0.9	10
7	PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models. <i>Nucleic Acids Research</i> , 2021, 49, D1321-D1327.	14.5	9
8	The B7-H3 Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. <i>Clinical Cancer Research</i> , 2021, 27, 2938-2946.	7.0	55
9	Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing. <i>Journal of Clinical Medicine</i> , 2021, 10, 1504.	2.4	3
10	Recent Developments in Nanomedicine for Pediatric Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1437.	2.4	11
11	In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). <i>Pediatric Blood and Cancer</i> , 2021, 68, e29304.	1.5	14
12	Prospective use of the single-mouse experimental design for the evaluation of PLX038A. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 251-263.	2.3	12
13	Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28606.	1.5	9
14	Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28222.	1.5	8
15	Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28098.	1.5	13
16	Evaluation of VTP50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28284.	1.5	9
17	Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts. <i>Clinical Cancer Research</i> , 2020, 26, 3012-3023.	7.0	11
18	Abstract LB-217: Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC). , 2020, , .		4

#	ARTICLE	IF	CITATIONS
19	Challenges and Opportunities for Childhood Cancer Drug Development. <i>Pharmacological Reviews</i> , 2019, 71, 671-697.	16.0	13
20	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. <i>Cell Reports</i> , 2019, 29, 1675-1689.e9.	6.4	103
21	Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27820.	1.5	16
22	Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27765.	1.5	19
23	Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma. <i>Frontiers in Oncology</i> , 2019, 9, 1416.	2.8	17
24	Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. <i>Clinical Cancer Research</i> , 2019, 25, 2278-2289.	7.0	57
25	Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26870.	1.5	9
26	Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26825.	1.5	21
27	Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL. <i>Clinical Cancer Research</i> , 2017, 23, 3744-3755.	7.0	16
28	The Use of Pediatric Patient-Derived Xenografts for Identifying Novel Agents and Combinations. <i>Molecular and Translational Medicine</i> , 2017, , 133-159.	0.4	2
29	Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26304.	1.5	20
30	Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26218.	1.5	86
31	Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26263.	1.5	15
32	Initial Testing (Stage 1) of MK-8242 "A Novel MDM2 Inhibitor" by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1744-1752.	1.5	27
33	Preclinical models of childhood cancer for the development of targeted therapies. <i>Drug Discovery Today: Disease Models</i> , 2016, 21, 3-9.	1.2	0
34	Identifying novel therapeutic agents using xenograft models of pediatric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 221-232.	2.3	12
35	Evaluation of Alternative <i>In Vivo</i> Drug Screening Methodology: A Single Mouse Analysis. <i>Cancer Research</i> , 2016, 76, 5798-5809.	0.9	52
36	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. <i>Blood</i> , 2016, 128, 1382-1395.	1.4	148

#	ARTICLE	IF	CITATIONS
37	Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2016, 63, 276-286.	1.5	28
38	Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. <i>Cancer Research</i> , 2016, 76, 4579-4591.	0.9	20
39	Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2016, 63, 443-450.	1.5	0
40	Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia. <i>Cancer Research</i> , 2016, 76, 2766-2777.	0.9	16
41	AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 1193-1202.	1.4	50
42	Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1897-1905.	1.5	14
43	Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional <i>in vivo</i> response to BMN 673. <i>Pediatric Blood and Cancer</i> , 2015, 62, 91-98.	1.5	65
44	Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane [®]) by the Pediatric Preclinical Testing Program (PPTP). <i>Pediatric Blood and Cancer</i> , 2015, 62, 1214-1221.	1.5	29
45	Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1768-1774.	1.5	15
46	Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1106-1109.	1.5	9
47	Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. <i>Frontiers in Oncology</i> , 2015, 5, 193.	2.8	14
48	Evaluation of the <i>In Vitro</i> and <i>In Vivo</i> Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 364-374.	4.1	49
49	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. <i>Clinical Cancer Research</i> , 2015, 21, 819-832.	7.0	100
50	Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 1395-1405.	7.0	43
51	Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1345-1352.	1.5	23
52	Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 922-924.	1.5	6
53	Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 380-382.	1.5	5
54	Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1972-1979.	1.5	7

#	ARTICLE	IF	CITATIONS
55	Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1486-1489.	1.5	19
56	Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 245-252.	1.5	37
57	¹²⁵ I-Np63 Promotes Pediatric Neuroblastoma and Osteosarcoma by Regulating Tumor Angiogenesis. <i>Cancer Research</i> , 2014, 74, 320-329.	0.9	51
58	FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3-FOXO1 Fusion Gene. <i>Clinical Cancer Research</i> , 2014, 20, 3884-3895.	7.0	12
59	Cell and Molecular Determinants of <i>In Vivo</i> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts. <i>Clinical Cancer Research</i> , 2014, 20, 4520-4531.	7.0	67
60	Initial testing (stage 1) of the notch inhibitor PF03084014, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1493-1496.	1.5	6
61	Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 158-164.	1.5	46
62	Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1816-1821.	1.5	35
63	Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling. <i>Blood</i> , 2014, 124, 969-969.	1.4	0
64	The application of radiation therapy to the pediatric preclinical testing program (PPTP): Results of a pilot study in rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 377-382.	1.5	10
65	Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 633-641.	1.5	55
66	Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 783-790.	1.5	13
67	Initial testing (stage 1) of the phosphatidylinositol 3-kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 791-798.	1.5	19
68	Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1325-1332.	1.5	77
69	Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an <i>In Vivo</i> Model of Childhood Astrocytoma. <i>Clinical Cancer Research</i> , 2013, 19, 6716-6729.	7.0	50
70	Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMG901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1860-1867.	1.5	27
71	Abstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib.. <i>Cancer Research</i> , 2013, 73, LB-353-LB-353.	0.9	6
72	Effective Targeting Of The P53/MDM2 Axis In Preclinical Models Of Infant MLL-Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 71-71.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 649-659.	4.1	60
74	Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a ß-secretase inhibitor targeting notch signaling. <i>Pediatric Blood and Cancer</i> , 2012, 58, 815-818.	1.5	31
75	Initial testing of JN26854165 (Serdemetan) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 329-332.	1.5	22
76	Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2012, 59, 753-755.	1.5	8
77	Testing of the Akt/PKB inhibitor MK2206 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 518-524.	1.5	36
78	Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 586-588.	1.5	33
79	Dual Inhibition of JAK/STAT and MAPK Pathways Results in Synergistic Cell Killing of JAK-Mutated Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 3562-3562.	1.4	2
80	Birinapant (TL32711), a Small Molecule Smac Mimetic, Induces Regressions in Childhood Acute Lymphoblastic Leukemia (ALL) Xenografts That Express TNF± and Synergizes with TNF± in Vitro – A Report From the Pediatric Preclinical Testing Program (PPTP). <i>Blood</i> , 2012, 120, 3565-3565.	1.4	3
81	The application of radiotherapy to the pediatric preclinical testing program: Results of a pilot study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9544-9544.	1.6	0
82	Molecular Therapy for Rhabdomyosarcoma. , 2010, , 425-458.		0
83	The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma. <i>Cancer Research</i> , 2009, 69, 7662-7671.	0.9	143
84	Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells. <i>Oncogene</i> , 2008, 27, 694-699.	5.9	19
85	Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1620-1628.	4.1	47
86	Pediatric oncology. <i>Current Opinion in Chemical Biology</i> , 2007, 11, 424-432.	6.1	13
87	Predicted mechanisms of resistance to mTOR inhibitors. <i>British Journal of Cancer</i> , 2006, 95, 955-960.	6.4	82
88	IRS-1: Auditing the effectiveness of mTOR inhibitors. <i>Cancer Cell</i> , 2006, 9, 153-155.	16.8	70
89	IGF-I mediated survival pathways in normal and malignant cells. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1766, 1-22.	7.4	111
90	Upstream CpG island methylation of thePAX3 gene in human rhabdomyosarcomas. <i>Pediatric Blood and Cancer</i> , 2005, 44, 328-337.	1.5	26

#	ARTICLE	IF	CITATIONS
91	Developing new agents for the treatment of childhood cancer. Current Opinion in Investigational Drugs, 2005, 6, 1215-27.	2.3	4